YGL034C Antibody

What is YGL034C protein and why is it studied in Saccharomyces cerevisiae?

YGL034C is a protein identified in Saccharomyces cerevisiae (Baker's yeast) through systematic genomic analysis. This protein is targeted by specific antibodies such as the polyclonal antibody product mentioned in the search results . Studying YGL034C contributes to our fundamental understanding of eukaryotic cellular processes using yeast as a model organism.

The protein is identified by its systematic name in the yeast genome database (YGL034C), which indicates its chromosomal location. Researchers investigate this protein to understand its function within cellular pathways and potential homology with proteins in higher organisms. The antibody specifically targets the YGL034C protein in the ATCC 204508 / S288c strain of Saccharomyces cerevisiae, which is a common laboratory strain used in molecular biology research .

What experimental applications is the YGL034C antibody validated for?

According to the product information, the YGL034C antibody has been specifically validated for ELISA (Enzyme-Linked Immunosorbent Assay) and Western Blot (WB) applications . These techniques represent core methodologies in protein research:

• ELISA allows for quantitative detection of YGL034C in solution

• Western Blotting enables detection of the protein after separation by electrophoresis, confirming molecular weight and expression levels

The antibody is explicitly labeled "For Research Use Only" and not validated for diagnostic or therapeutic procedures . This distinction is critical as the validation process for research applications follows different standards than clinical applications, focusing on analytical performance rather than clinical utility.

What are the optimal storage conditions for maintaining YGL034C antibody efficacy?

Maintaining antibody efficacy requires strict adherence to proper storage conditions. The product specifications indicate that upon receipt, YGL034C antibody should be stored at either -20°C or -80°C . The documentation specifically warns against repeated freeze-thaw cycles, which can lead to protein denaturation and decreased antibody performance.

The antibody is provided in liquid form with a specific storage buffer composition:

• Preservative: 0.03% Proclin 300

• Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

The high glycerol content (50%) serves as a cryoprotectant, preventing destructive ice crystal formation during freezing while maintaining the antibody in a partially hydrated state. The neutral pH buffer (pH 7.4) minimizes chemical degradation, while the Proclin 300 inhibits microbial growth during handling and storage.

How should I implement the "fit for purpose" validation approach for YGL034C antibody in my experimental system?

The concept of "fit for purpose" antibody validation, as described in current literature, recognizes that antibody performance is highly context-dependent . For YGL034C antibody, implement this approach through these methodological steps:

First, define your specific experimental context by documenting:

• The exact application (Western blot, ELISA, immunoprecipitation)

• Sample preparation methods specific to your yeast strains

• Detection systems and sensitivity requirements

Second, develop a validation protocol that includes:

• Specificity testing using genetic controls (comparing wild-type vs. YGL034C knockout yeast strains)

• A mixed population experiment where defined ratios of positive and negative cells are analyzed to verify the antibody's ability to distinguish between populations

• Cross-validation using orthogonal detection methods (e.g., mass spectrometry)

As emphasized in the literature, isotype controls alone are insufficient for establishing specificity . The mixed population experiment is particularly critical as it directly assesses whether the antibody can accurately quantify heterogeneity within your samples across a defined dynamic range .

Document all validation steps thoroughly, as this documentation serves as evidence that the antibody is indeed "fit for purpose" in your specific experimental context.

What strategies can address batch-to-batch variability in polyclonal YGL034C antibody preparations?

Polyclonal antibodies like the YGL034C antibody exhibit inherent batch-to-batch variability due to their production in animals and purification from antisera. This variability requires systematic management strategies:

• Bridging Studies Protocol:

  • When transitioning to a new lot, perform side-by-side comparison experiments

  • Test multiple dilutions of both old and new lots against the same samples

  • Document differences in sensitivity, specificity, and optimal working dilutions

  • Create calibration curves that allow normalization between batches

• Reference Standard Development:

  • Create and freeze aliquots of a well-characterized positive control sample

  • Use this standard with each new experiment to calibrate results

  • Consider creating a dilution series of purified target protein as an absolute reference

• Expanded Experimental Controls:

  • Include more comprehensive positive and negative controls with each experiment

  • Document the expected signal pattern for these controls with each antibody lot

  • Implement negative cell type controls alongside isotype controls to ensure specificity

• Lot Reservation Strategy:

  • For critical long-term studies, consider purchasing multiple vials from the same lot

  • Document lot numbers in all experimental records and publications

  • Communicate with colleagues about shared resources to maintain consistency in collaborative work

These methodological approaches cannot eliminate batch-to-batch variability, but they provide a systematic framework for managing its impact on experimental results and interpretations.

What experimental controls are essential when using YGL034C antibody to quantify protein expression in different yeast strains?

Quantifying YGL034C expression across different yeast strains requires rigorous controls to ensure reliable comparisons. Based on antibody validation principles, implement these essential controls:

• Genetic Specificity Controls:

  • YGL034C deletion strains in each genetic background being studied

  • Overexpression systems for positive control calibration

  • Wild-type reference strains with documented YGL034C expression levels

• Sample Preparation Controls:

  • Standardized cell lysis protocols validated for each strain

  • Protein concentration determination using multiple methods (Bradford and BCA)

  • Time-course sampling to account for potential differences in growth phases

• Technical Validation Controls:

  • Loading controls appropriate for each strain (e.g., total protein stain)

  • Dilution series of samples to verify linear detection range

  • Secondary-only controls to assess non-specific binding

• Quantitative Normalization Framework:

  Control Type	Purpose	Implementation
  Internal reference	Account for lane-to-lane variations	Include constitutively expressed protein (e.g., PGK1)
  Cross-strain calibrator	Address strain-specific extraction efficiency	Spike-in controlled amounts of recombinant protein
  Dynamic range verifier	Ensure measurements within linear range	Include dilution series (100%, 50%, 25%) for each strain
  Background control	Establish baseline signal	Process YGL034C deletion strain identically

• Statistical Analysis Controls:

  • Minimum of three biological replicates per strain

  • Technical duplicates for each biological sample

  • Randomization of sample processing order to minimize systematic errors

The literature emphasizes that experimental controls must be tailored to the specific purpose of the protocol, following the "fit for purpose" concept . This comprehensive control strategy ensures that observed differences in YGL034C expression between strains reflect true biological variation rather than technical artifacts.

How can I distinguish between specific YGL034C signal and non-specific binding in Western blot applications?

Distinguishing specific from non-specific signals requires a methodological approach combining experimental controls and analytical techniques:

• Essential Control Experiments:

  • Compare wild-type and YGL034C knockout yeast samples processed identically

  • Perform peptide competition assays by pre-incubating the antibody with the immunizing peptide

  • Include multiple negative controls (unrelated yeast strains, non-yeast samples)

• Signal Characteristic Analysis:

  • Specific YGL034C binding should produce a band at the predicted molecular weight

  • Non-specific binding often appears as multiple bands or smears across various molecular weights

  • True specific signal should diminish in knockouts and after peptide competition

• Optimization-Based Approach:

  • Systematically increase washing stringency (higher salt concentration, longer wash times)

  • Test different blocking agents (BSA, milk, commercial blockers) to identify optimal conditions

  • Perform dilution series of both primary and secondary antibodies

• Analytical Verification:

  • Compile results from multiple experiments to create a signature profile for specific binding

  • Document how this profile responds to experimental manipulations expected to affect YGL034C

  • Compare results with orthogonal detection methods when possible

As emphasized in the literature, negative control cell types are critical for evaluating whether a protocol can reliably distinguish positive from negative populations . The use of isotype controls alone is insufficient, as demonstrated by cases where samples can show signal above isotype controls while still representing non-specific binding .

What troubleshooting approaches are recommended when YGL034C antibody shows inconsistent results between experiments?

Inconsistent results with YGL034C antibody require systematic troubleshooting focusing on both technical and biological variables:

• Sample Preparation Variables:

  • Cell lysis conditions (buffer composition, mechanical disruption method)

  • Protein extraction efficiency (particularly important for membrane-associated proteins)

  • Sample storage conditions and freeze-thaw history

  • Protein quantification method accuracy and reproducibility

• Antibody Handling Assessment:

  • Antibody storage conditions and potential degradation

  • Freeze-thaw cycles and aliquoting practices

  • Working dilution preparation method and timing

  • Lot-to-lot variations if multiple lots have been used

• Systematic Protocol Documentation:

  Parameter	Experiment 1	Experiment 2	Experiment 3	Notes on Differences
  Sample lysis method
  Protein concentration
  Gel percentage
  Transfer method
  Blocking solution
  Antibody dilution
  Wash protocol
  Detection method

• Biological Variable Control:

  • Yeast growth phase at harvest (log vs. stationary)

  • Media composition and growth conditions

  • Cell density and metabolic state

  • Potential post-translational modifications affecting epitope accessibility

The literature emphasizes that sample preparation conditions can significantly impact antibody performance, with effects ranging from subtle to substantial . Some sample preparation methods may affect both positive and negative populations similarly, while others may create differential effects that complicate interpretation .

What statistical approaches should be used when analyzing semi-quantitative data from YGL034C antibody experiments?

Semi-quantitative analysis of YGL034C antibody data requires statistical approaches that acknowledge the limitations of antibody-based detection while maximizing rigor:

• Data Collection Design:

  • Minimum of three biological replicates (independent yeast cultures)

  • Technical duplicates for each sample

  • Inclusion of calibration samples for inter-experiment normalization

• Normalization Methods:

  • Select appropriate internal controls based on experimental context

  • Consider ratiometric approaches comparing YGL034C signal to reference proteins

  • Evaluate total protein normalization as an alternative to single-protein references

• Statistical Analysis Framework:

  • Test data for normality using Shapiro-Wilk or similar tests

  • For normally distributed data: ANOVA or t-tests with appropriate corrections for multiple comparisons

  • For non-normal distributions: non-parametric alternatives (Mann-Whitney, Kruskal-Wallis)

• Quantification Confidence Metrics:

  Statistical Parameter	Threshold for Confidence	Purpose
  Coefficient of variation	<15% for technical replicates	Assess technical reproducibility
  Signal-to-noise ratio	>3:1	Ensure signal exceeds background
  p-value	<0.05 after multiple testing correction	Establish statistical significance
  Effect size	Dependent on experimental context	Assess biological relevance

• Reporting Standards:

  • Include raw data alongside normalized results

  • Document image acquisition settings and analysis parameters

  • Clearly state statistical tests and significance thresholds

  • Consider visualization methods that show data distribution (box plots, scatter plots)

This approach acknowledges that antibody-based measurements contain inherent variability while providing a framework for maximizing statistical rigor and reproducibility.

How can I optimize immunoprecipitation protocols for protein interaction studies using YGL034C antibody?

Optimizing immunoprecipitation (IP) protocols for YGL034C protein interaction studies requires systematic refinement of multiple parameters:

• Cell Lysis Optimization:

  • Test multiple lysis buffers varying in detergent type and concentration

  • Compare mechanical disruption methods (e.g., glass beads, sonication)

  • Evaluate lysate clarification approaches (centrifugation speed/duration)

  • Determine optimal protein concentration for IP input

• Antibody Coupling Strategy:

  • Compare direct addition to lysate versus pre-coupling to beads

  • Test different antibody-to-bead ratios (typically 2-10 μg antibody per 50 μl bead slurry)

  • Evaluate covalent coupling options for reduced antibody contamination in eluates

  • Determine optimal antibody incubation time and temperature

• Washing Stringency Calibration:

  • Develop a wash buffer matrix varying salt concentration (150-500 mM NaCl)

  • Test detergent concentrations in wash buffers (0.1-1%)

  • Determine optimal number of washes (typically 3-5)

  • Consider adding competing agents to reduce non-specific binding

• Elution Method Selection:

  Elution Method	Advantages	Disadvantages	Best Applications
  Low pH (glycine)	Efficient, maintains antibody integrity	May denature sensitive complexes	Western blot analysis
  SDS/heat	Highly efficient recovery	Destroys protein-protein interactions	Mass spectrometry
  Competing peptide	Preserves native complexes	Expensive, can be inefficient	Functional assays
  On-bead digestion	Minimizes manipulation	Limited to mass spectrometry	Proteomic analysis

• Validation Controls:

  • Perform parallel IPs in YGL034C knockout strains to identify non-specific binding

  • Include IgG control IPs to establish background binding profiles

  • Analyze both supernatant and pellet fractions to assess IP efficiency

  • Consider sequential IPs to increase purity of complexes

This systematic optimization approach ensures that the YGL034C antibody can be effectively used to isolate native protein complexes while minimizing contaminants and artifacts.

How do correlates of protection concepts from immunology relate to antibody validation for research applications like YGL034C?

While YGL034C antibody is used in basic research rather than protective immunity studies, correlates of protection (CoP) concepts from immunology offer valuable methodological parallels for antibody validation:

• Threshold Determination Methodologies:
  In vaccine research, establishing antibody thresholds that correlate with protection involves statistical modeling of antibody levels and outcomes . Similarly, for research antibodies like YGL034C, we can establish signal thresholds that reliably distinguish positive from negative samples:

  • Analyze signal distribution across known positive and negative populations

  • Use receiver operating characteristic (ROC) curves to identify optimal cutoff values

  • Implement statistical approaches like those used in vaccine CoP studies to define confidence intervals around these thresholds

• Functional vs. Binding Correlation:
  Vaccine studies distinguish between antibody binding and functional activity . Similarly, for research antibodies:

  • Establish correlation between antibody binding signal and functional outcomes

  • Determine whether binding signal intensity accurately predicts experimental outcomes

  • Recognize that different applications may require different validation thresholds

• Application-Specific Validation Metrics:
  Just as CoP thresholds vary by pathogen and vaccine type , research antibody performance metrics should be application-specific:

  Application	Primary Validation Metric	Secondary Metrics	Threshold Determination Method
  Western blot	Signal:noise at correct MW	Background levels	Signal ratio vs. negative control
  ELISA	Dynamic range	Lower limit of detection	Standard curve analysis
  Immunofluorescence	Localization specificity	Background fluorescence	Comparison to genetic controls
  IP	Enrichment factor	Non-specific binding	Recovery of known interactors

• Standardization Approaches:
  Vaccine CoP studies emphasize standardized assays and reference materials . For YGL034C antibody:

  • Develop standard operating procedures with defined acceptance criteria

  • Create reference samples that can be shared between laboratories

  • Establish common reporting metrics to facilitate cross-lab comparison

The systematic, quantitative approaches used in correlates of protection studies provide a methodological framework that can enhance rigor in research antibody validation, despite the different contexts.

What novel approaches can improve YGL034C antibody specificity verification beyond traditional methods?

Advanced techniques for verifying YGL034C antibody specificity can overcome limitations of traditional approaches:

• CRISPR-Based Validation Systems:

  • Generate tag knock-in strains where YGL034C is fused to epitope tags

  • Create precise gene edits introducing point mutations in antibody epitopes

  • Develop degron-tagged versions of YGL034C for inducible depletion controls

  • Compare antibody signal before and after induced degradation

• Proximity Labeling Integration:

  • Couple YGL034C detection with proximity labeling technologies

  • Verify that proteins identified by proximity methods match known YGL034C interactors

  • Compare antibody-based detection with direct visualization of labeled proteins

  • Implement this approach similar to the target-guided proximity labeling mentioned in the search results

• Orthogonal Multi-omic Validation:

  • Correlate antibody signal with mRNA levels (RNA-seq)

  • Compare antibody-detected interactions with crosslinking mass spectrometry data

  • Validate localization with fractionation studies and mass spectrometry

  • Create integrated datasets showing concordance across multiple detection methods

• Advanced Imaging Verification:

  • Apply super-resolution microscopy to precisely define subcellular localization

  • Use live-cell imaging with fluorescent protein fusions as reference standards

  • Implement multiplexed imaging with orthogonal probes targeting different epitopes

  • Quantify co-localization coefficients between antibody signal and orthogonal markers

• Computational Prediction Integration:

  • Use structural biology and epitope prediction algorithms to map antibody binding sites

  • Identify potential cross-reactive proteins through sequence and structural homology

  • Model effects of sample preparation on epitope accessibility

  • Create computational frameworks for predicting antibody performance across applications

These advanced approaches move beyond simple presence/absence tests to provide quantitative metrics of antibody specificity and performance across different experimental contexts, addressing the limitations of traditional validation methods highlighted in the literature .

How should researchers report YGL034C antibody validation in publications to enhance reproducibility?

Comprehensive reporting of YGL034C antibody validation enhances experimental reproducibility through structured documentation:

• Essential Reporting Elements:

  • Complete antibody identifier (manufacturer, catalog number, lot number, RRID)

  • Host species, clonality, and immunogen details

  • Validation experiments conducted specifically for the reported application

  • Detailed methods for determining optimal working concentration

  • All sample preparation steps that may affect epitope accessibility

• Application-Specific Documentation:

  • For Western blotting: gel percentage, transfer method, blocking conditions, exposure parameters

  • For ELISA: plate type, coating conditions, detection system specifics

  • For immunofluorescence: fixation method, permeabilization protocol, mounting media

  • For all applications: incubation times, temperatures, and buffer compositions

• Validation Evidence Requirements:

  • Images of complete blots including molecular weight markers

  • Controls demonstrating specificity (knockout/knockdown, peptide competition)

  • Quantitative metrics of performance (signal-to-noise ratio, coefficients of variation)

  • Raw data availability statement (repository information)

• Standardized Reporting Format:

  Validation Parameter	Evidence Provided	Limitations	Alternative Approaches Considered
  Specificity
  Sensitivity
  Reproducibility
  Optimization

The literature emphasizes that publishers should adopt standardized, comprehensive reporting requirements to ensure technical details accompany antibody-based studies . This approach follows similar calls for standardized reporting in other antibody applications such as immunoblotting and immunohistochemistry .

What quantitative metrics best assess YGL034C antibody performance across different experimental contexts?

Quantitative performance metrics provide objective measures for YGL034C antibody evaluation:

• Specificity Metrics:

  • Positive Predictive Value (PPV): proportion of positive signals that are true positives

  • Signal Ratio: comparison of signal between wild-type and knockout samples

  • Epitope Competition Index: signal reduction percentage after peptide competition

  • Cross-reactivity Profile: systematic assessment of signal against related proteins

• Sensitivity Parameters:

  • Limit of Detection (LoD): lowest concentration reliably distinguishable from background

  • Dynamic Range: ratio between minimum and maximum detectable concentration

  • EC50: antibody concentration yielding half-maximal signal

  • Signal-to-Background Ratio: specific signal divided by background in negative controls

• Reproducibility Measurements:

  • Intra-assay Coefficient of Variation (CV): variation between technical replicates

  • Inter-assay CV: variation across independent experiments

  • Lot-to-lot Consistency Index: correlation coefficient between antibody lots

  • Robustness Factor: sensitivity to minor protocol variations

• Application-Specific Metrics:

  Application	Primary Metric	Calculation Method	Acceptable Range
  Western blot	Band specificity score	Signal at correct MW / total signal	>0.8
  ELISA	Z-factor	1-[(3σp+3σn)/|μp-μn|]	>0.5
  IP	Enrichment factor	Target in IP / target in input	>10
  IF	Localization concordance	Overlap with orthogonal markers	>0.7

• Integrated Performance Score:

  • Combine metrics relevant to specific application

  • Weight components based on experimental priorities

  • Establish minimum thresholds for acceptable performance

  • Document score for each experimental condition

This quantitative approach aligns with methodologies used in correlates of protection studies and provides objective criteria for evaluating antibody performance across different experimental contexts.

How can researchers distinguish between antibody failures and biological variations when studying YGL034C in diverse yeast strains?

Distinguishing antibody technical failures from true biological variation requires a structured investigative approach:

• Systematic Exclusion Strategy:

  • Implement controlled experiments that systematically rule out technical variables

  • Test antibody performance with recombinant YGL034C protein from different strains

  • Create chimeric constructs to identify strain-specific epitope variations

  • Develop a decision tree for attributing observed variations to technical versus biological factors

• Orthogonal Validation Methods:

  • Compare antibody results with strain-specific mRNA levels

  • Verify protein expression using epitope tagging in each strain background

  • Implement mass spectrometry-based quantification as a reference method

  • Correlate antibody signal with functional assays for YGL034C activity

• Strain-Specific Epitope Analysis:

  • Sequence YGL034C across strains to identify potential polymorphisms

  • Map immunogen sequence to strain-specific protein sequences

  • Predict epitope accessibility in different genetic backgrounds

  • Test synthetic peptides representing strain-specific variants

• Technical Variable Isolation:

  Variable Type	Isolation Method	Expected Pattern if Technical	Expected Pattern if Biological
  Sample preparation	Process identical samples with multiple methods	Consistent strain differences across methods	Method-dependent strain differences
  Antibody affinity	Antibody titration curves for each strain	Parallel curves with offset	Differently shaped curves
  Epitope accessibility	Denaturation series	Convergence of signals with increasing denaturation	Persistent differences regardless of denaturation
  Protocol sensitivity	Detection system comparison	Consistent strain ranking across systems	System-dependent strain rankings

• Statistical Discrimination Framework:

  • Evaluate variance components attributable to technical vs. biological factors

  • Implement mixed-effects models incorporating both sources of variation

  • Calculate intraclass correlation coefficients to quantify relative contributions

  • Establish confidence intervals for biological differences

This multifaceted approach acknowledges that what initially appears as antibody failure may reflect genuine biological differences in epitope structure or accessibility across strains, requiring rigorous investigation rather than simple troubleshooting.